Early add-on use of belimumab as induction therapy for patients with childhood-onset systemic lupus erythematosus-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Early add-on use of belimumab as induction therapy for patients with childhood-onset systemic lupus erythematosus

Published:2024-03-08 Issue:5 Volume:33 Page:543-544
ISSN:0961-2033
Container-title:Lupus
language:en
Short-container-title:Lupus

Author:

Hashimoto Shun¹,Fujita Masashi¹,Aizawa Tomomi¹²,Watanabe Shojiro¹³,Tsugawa Koji¹,Tanaka Hiroshi¹⁴^ORCID

Affiliation:

1. Department of Pediatrics, Hirosaki University Hospital, Hirosaki, Japan

2. Niji-iro Children’s Clinic, Hirosaki, Japan

3. Department of Pediatrics, Ehime University Graduate School of Medicine, Toon City, Japan

4. Department of School Health Science, Hirosaki University Faculty of Education, Hirosaki, Japan

Publisher

SAGE Publications

Link

https://journals.sagepub.com/doi/pdf/10.1177/09612033241238867

Reference8 articles.

1. 10 Years of belimumab experience: What have we learnt?

2. Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial

3. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis

4. Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population

5. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP